
Gatlan by Immortal Male, Inc.
Raising nowOperatingImmortal Male, Inc.
Biotech · Plano, TX
Founded by Josh Duhamel, Gatlan by Immortal Male, Inc., ("Gatlan") is a provider-led, consumer health platform, built to make proactive care feel more trusted, accessible, and stigma-free. Because the future of healthcare isn’t just treatment, it’s optimization.
This company has an open fundraising round.
Financials
FY2024–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note roundsDashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Fundraising history
Team
4 people
Tyler Williamson is the Chief Executive Officer of Gatlan and an experienced executive with a background spanning healthcare-adjacent technology, global consumer brands, and regulated industries. He has led organizations through early formation, growth, and large-scale operations, with experience managing complex, multi-stakeholder environments and building organizations designed for long-term sustainability. Mr. Williamson was an early member of the Beats by Dre organization and held leadership roles during the company’s formative growth period, culminating in its acquisition by Apple Inc. He has also served in senior executive positions at Apple, PepsiCo, and Kraft Foods, where he oversaw cross-functional teams and large-scale initiatives across product development, operations, and market expansion. A former military officer, Mr. Williamson brings a disciplined, mission-driven leadership approach with an emphasis on accountability, talent development, and organizational integrity. His experience leading regulated, high-impact businesses informs his focus on patient safety, operational rigor, and responsible innovation in healthcare. Tyler does not currently draw a salary from Gatlan. See the Form C for more information.

Yonathan Azran is the Founder and Managing Partner of 1116 Partners, a strategic accounting and fractional CFO firm dedicated to helping growth-stage companies build scalable finance and accounting functions. Since founding the firm in 2016, Yonathan has focused on providing founders and leadership teams with the financial clarity, operational discipline, and strategic guidance needed to confidently scale their businesses. A graduate of the USC Marshall School of Business (2008), Yonathan has developed deep expertise across accounting, financial operations, strategic finance, and capital planning. His experience spans a broad range of industries, including eCommerce, retail, SaaS, fashion, consumer products, and professional services, allowing him to bring industry-specific insight while applying best-in-class financial practices. Under Yonathan's leadership, 1116 Partners has served as the accounting and finance partner for high-growth companies including Jaanuu, RtA, Jonathan Simkhai, Evite, Toccin, Lifeforce, Venus et Fleur, and numerous other emerging brands. Collectively, these companies have generated more than $100 million in annual revenue and have successfully raised over $100 million in growth capital. Throughout his career, Yonathan has led finance organizations through complex accounting transformations, audits, Quality of Earnings (QoE) engagements, lender field examinations, fundraising processes, ERP implementations, and strategic planning initiatives. His expertise includes revenue recognition, inventory accounting, financial modeling, cash flow management, operational KPI development, and building accounting infrastructures capable of supporting rapid growth. 1116 Partners was founded on the belief that growing companies deserve finance leadership that extends beyond bookkeeping and compliance. Today, the firm's team integrates directly with clients' organizations, acting as an extension of management by combining strategic CFO guidance with best-in-class accounting execution. Leveraging an experienced global team and scalable operating model, 1116 Partners supports businesses from pre-revenue startups through mature growth-stage companies. Yonathan is passionate about helping founders transform financial complexity into actionable business intelligence. Whether optimizing contribution margins for eCommerce brands, developing KPI frameworks for SaaS businesses, preparing companies for institutional investment, or strengthening financial operations, his objective remains the same: to ensure finance becomes a strategic advantage that enables sustainable, profitable growth. Yonathan provides CFO services to the Company on a fractional, contracted basis through 1116 Partners, and is not an employee of the Company.

Fabian Calvo is a seasoned pharmaceutical executive with extensive experience in the founding, operation, and scaling of advanced healthcare and life sciences companies. His career reflects deep expertise across pharmaceutical manufacturing, supply chain operations, and regulatory-compliant distribution in highly regulated environments. Mr. Calvo has led multiple organizations involved in the development, manufacturing, and distribution of prescription drugs and critical active pharmaceutical ingredients (APIs). He brings particular operational strength in the importation, qualification, and domestic distribution of APIs, with a demonstrated ability to build resilient, compliant supply chains that support patient access and continuity of care. Throughout his career, Mr. Calvo has worked closely with regulatory bodies and compliance teams to navigate complex pharmaceutical regulatory frameworks. His expertise spans regulatory strategy, quality systems, and operational readiness, enabling organizations to meet rigorous industry standards while operating efficiently at scale. His experience provides Gatlan with practical, execution-focused leadership grounded in regulatory rigor and operational excellence.

Josh Duhamel is the Founder of Gatlan, a performance healthcare company built around a simple idea: getting high-quality care should be easier, more personal, and more convenient. After seeing how difficult it can be for people to get the care they need, Josh helped create Gatlan to give patients better access to experienced medical providers and modern treatment options without sacrificing the doctor-patient relationship. As an actor and producer, Josh has spent decades connecting with audiences around the world. At Gatlan, he uses that platform to help bring greater attention to men’s and women’s health, longevity, and the importance of taking a more proactive approach to healthcare. Josh remains closely involved in Gatlan’s direction, brand, and mission as the company works to make personalized, performance healthcare more accessible to people across the country.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form CSep 24, 20260002144946-26-000003EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.